Reverse transcription polymerase chain reaction

Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, June 2, 2021

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purchase an aggregate of 144,580 shares of its common stock to eighteen new employees.

Key Points: 
  • Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purchase an aggregate of 144,580 shares of its common stock to eighteen new employees.
  • These inducement stock options have a grant date of May 31, 2021, and were granted as inducements material to the new employees entering into employment with Biocept in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The inducement stock options are subject to the terms and conditions of Biocepts Amended and Restated 2013 Equity Incentive Plan.
  • Biocept also is leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.

Therma Bright Provides Update on Brazilian Clinical Study

Retrieved on: 
Thursday, May 27, 2021

Company advances final validation efforts of its AcuVid(TM) COVID-19 Rapid Antigen Saliva Test

Key Points: 
  • Toronto, Ontario--(Newsfile Corp. - May 27, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of its smart-enabled AcuVid COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to provide the following update on its Brazilian clinical study of its innovative 15- minute COVID-19 antigen saliva test.
  • "This key clinical study requires that each tested participant take our AcuVid COVID-19 Rapid Antigen Saliva Test as well as a 24-hour RT-PCR test which will be used as the gold-standard comparator test," shared Rob Fia, Therma Bright's CEO.
  • It also requires our test solution to achieve a minimum of 30 positive and 30 negative specimens in the study.
  • The Company looks to provide a further update upon receipt of the clinical study results.

Thermo Fisher Scientific's TaqPath COVID-19 CE-IVD RT-PCR Kit Now Available for the Incoming International Travel Quarantine Protocol Testing in the United Kingdom

Retrieved on: 
Thursday, May 27, 2021

The United Kingdom has instituted quarantine rules for travellers entering the country that vary depending on the country of departure, but most people will be legally required to quarantine for ten days upon arrival.

Key Points: 
  • The United Kingdom has instituted quarantine rules for travellers entering the country that vary depending on the country of departure, but most people will be legally required to quarantine for ten days upon arrival.
  • On days two and eight of their isolation, those travellers are obliged to take a PCR test to monitor for an active SARS-CoV-2 infection.
  • Thermo Fisher's TaqPath kit is now permitted to be used by laboratories and clinics in that surveillance.
  • The TaqPathCOVID-19 CE-IVD RT PCR Kit received initial CE-IVD approval in March 2020 and is compatible with most widely used real-time PCR instruments.

GT Molecular Launches Highly Sensitive Multiplexed PCR Tests for the Indian Coronavirus Variant

Retrieved on: 
Wednesday, May 19, 2021

b"FORT COLLINS, Colo., May 19, 2021 /PRNewswire/ -- GT Molecular, a company providing multiplexed, ultrasensitive PCR assays for wastewater-based epidemiology, cancer and pathogen panels for clinical labs, has started shipping its sensitive PCR tests to monitor the coronavirus variant, B.1.617.

Key Points: 
  • b"FORT COLLINS, Colo., May 19, 2021 /PRNewswire/ -- GT Molecular, a company providing multiplexed, ultrasensitive PCR assays for wastewater-based epidemiology, cancer and pathogen panels for clinical labs, has started shipping its sensitive PCR tests to monitor the coronavirus variant, B.1.617.
  • The virus was first spotted in India and upgraded to a global variant of concern by the WHO.
  • It is sometimes referred to as the double mutant because it contains two mutations of concern and has been reported to be highly contagious and potentially capable of evading the immune system.\nA national wastewater-based epidemiology testing service in which sewage from communities around the country is tested for the presence of the key mutations that define the B.1.617 double mutant variant from India.\nUltrasensitive RT-PCR and dPCR reagent kits to empower academic, commercial, and public testing laboratories:\nThese new offerings add to GT Molecular's growing molecular assay catalog that includes SARS-CoV-2 multi-variant tests, cancer panels, multiplexed pathogen panels for clinical labs and quantitative standards.\nGT Molecular is a leader in providing highly customizable, ultrasensitive digital PCR and qPCR tests.
  • GTM's molecular app technology is an easy-to-use, end-to-end solution for rapid deployment and provides reliable and consistent measurements while detecting as little as 1-3 molecules of target nucleic acid.\n"

Eurofins at the Forefront of Innovation with New Developments for Detection and Identification of Emerging COVID-19 Variants of Concern

Retrieved on: 
Monday, May 17, 2021

b'Eurofins Technologies continues to develop a range of diagnostic solutions for COVID-19, particularly in response to the threat of emerging mutations.

Key Points: 
  • b'Eurofins Technologies continues to develop a range of diagnostic solutions for COVID-19, particularly in response to the threat of emerging mutations.
  • Eurofins Technologies will continue to invest in R&D to develop further reliable, high-quality testing solutions for the SARS-CoV-2 virus and its variants.\nGSD NovaPrime\xc2\xae Plus SARS-CoV-2 kit is a multiplex RT-PCR that can detect a SARS-CoV-2 infection and identify mutations of concern in one reaction.
  • It is of relevance to the global pandemic situation as this mutation is related to both an increase in infectivity and reduction of immune response in vaccinated subjects.
  • With over 50,000 staff across a network of more than 800 laboratories in over 50 countries, Eurofins\xe2\x80\x99 companies offer a portfolio of over 200,000 analytical methods.\nEurofins Shares are listed on Euronext Paris Stock Exchange.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210516005032/en/\n'

Global PCR and Realtime PCR Testing Market Report 2021: COVID-19 Impacts, Implications and Growth Forecast to 2025 & 2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 5, 2021

Global Polymerase Chain Reaction (PCR) And Real-time Polymerase Chain Reaction (PCR) Testing Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion\n6.2.

Key Points: 
  • Global Polymerase Chain Reaction (PCR) And Real-time Polymerase Chain Reaction (PCR) Testing Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion\n6.2.
  • Global Polymerase Chain Reaction (PCR) And Real-time Polymerase Chain Reaction (PCR) Testing Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion\n6.3.
  • Global Polymerase Chain Reaction (PCR) And Real-time Polymerase Chain Reaction (PCR) Testing Market, Split By Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion\n7.2.
  • Global Polymerase Chain Reaction (PCR) And Real-time Polymerase Chain Reaction (PCR) Testing Market, Split By Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion\n'

Biocept to Report First Quarter 2021 Financial Results and Host Investor Conference Call on May 12, 2021

Retrieved on: 
Wednesday, May 5, 2021

In addition to its broad portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide\xe2\x84\xa2 cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system.

Key Points: 
  • In addition to its broad portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide\xe2\x84\xa2 cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system.
  • Biocept\xe2\x80\x99s patented Target Selector\xe2\x84\xa2 technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood.
  • Biocept also is leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.
  • Follow Biocept on Facebook , LinkedIn and Twitter .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210505005026/en/\n'

Global COVID-19 Sample Collection Kits Market Report 2021-2028: Focus on Swabs, Viral Transport Media, Blood Collection Kits, Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 29, 2021

b'The "COVID-19 Sample Collection Kits Market Share, Size, Trends, Industry Analysis Report, By Product; By Application; By Collection Site, By Regions; Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com\'s offering.\nAsia Pacific COVID-19 sample collection kits industry is expected to witness a lucrative growth rate over the assessment period.

Key Points: 
  • b'The "COVID-19 Sample Collection Kits Market Share, Size, Trends, Industry Analysis Report, By Product; By Application; By Collection Site, By Regions; Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com\'s offering.\nAsia Pacific COVID-19 sample collection kits industry is expected to witness a lucrative growth rate over the assessment period.
  • For instance, in November 2020, ICMR introduced an ambulatory COVID-19 RT-PCR lab at its facility.
  • The government has also announced plans to establish more labs to boost COVID-19 testing.\nIn 2020, the swabs COVID-19 sample kits industry segment accounted for the largest share.
  • The company has also received additional funding from the Paycheck Protection Program.\nHowever, the blood collection kits segment is projected to witness a lucrative market growth rate over the assessment period.

Biocept to Supply COVID-19 Testing Through Partnership With the Foundation for California Community Colleges

Retrieved on: 
Wednesday, April 28, 2021

Sales, Vice President of Program Development at the Foundation for California Community Colleges.\nBiocept will provide colleges with PCR-based COVID-19 testing, which detects the genetic information of the virus, through its CLIA-certified, CAP-accredited San Diego laboratory.

Key Points: 
  • Sales, Vice President of Program Development at the Foundation for California Community Colleges.\nBiocept will provide colleges with PCR-based COVID-19 testing, which detects the genetic information of the virus, through its CLIA-certified, CAP-accredited San Diego laboratory.
  • The assay detects the presence of SARS-CoV-2 and is intended for use with patients who meet current guidance for evaluation of infection with COVID-19.
  • The Foundation\'s mission is to benefit, support, and enhance the missions of the California Community Colleges system, the largest higher education system in the nation.
  • Biocept also is leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.

Biocept Provides Update on COVID-19 Testing with More than 350,000 Samples Received to Date

Retrieved on: 
Wednesday, April 14, 2021

(Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that since the Company began offering SARS-CoV-2 testing services in June 2020, it has now received more than 350,000 samples for testing.

Key Points: 
  • (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that since the Company began offering SARS-CoV-2 testing services in June 2020, it has now received more than 350,000 samples for testing.
  • Biocept also is leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.
  • The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release.
  • We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law.